| Budget Amount *help |
¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Research Abstract |
It became clear that Langerhans cells (LCs) in the epidermis of volunteer, who took Maraviroc (MVC), had very strong resistance for HIV infection, suggesting that MVC; the agent developed as an AIDS therapeutic drug has been demonstrated as a useful oral micro beside. In addition, in the in vitro HIV infection experiment with monocyte-derived LCs, it was suggested that EFdA and MVC had a superior suppressant effect against HIV infection, and that EFdA can be practically used as micro beside.
|
